Diagnostic value of serum versus plasma phospho-tau for Alzheimer’s disease
Rattachement africain : se, be, gb, us. Niveau de preuve : code pays fourni par la source.
Le résumé fourni par la source
Abstract Background Blood phosphorylated tau (p-tau) forms are promising Alzheimer’s disease (AD) biomarkers, but validation in matrices other than ethylenediaminetetraacetic acid (EDTA) plasma is limited. Firstly, we assessed the diagnostic potential of p-tau231 and p-tau181 in paired plasma and serum samples. Secondly, we compared serum and cerebrospinal fluid (CSF) samples from biomarker-positive AD and biomarker-negative control participants. Methods We studied three independent cohorts ( n =115 total): cohorts 1 and 2 included individuals with paired plasma and serum, while cohort 3 included paired serum and CSF. Blood-based p-tau231 and p-tau181 were measured using in-house or commercial single molecule array (Simoa) methods. Results Serum and plasma p-tau231 and p-tau181 were two- to three-fold increased in biomarker-positive AD versus biomarker-negative controls ( P ≤0.0008). Serum p-tau231 separated diagnostic groups with area under the curve (AUC) of 82.2% (cohort 3) to 88.2% (cohort 1) compared with 90.2% (cohort 1) for plasma. Similarly, p-tau181 showed AUC of 89.6% (cohort 1) to 89.8% (cohort 3) in serum versus 85.4% in plasma (cohort 1). P-tau231 and p-tau181 correlated slightly better in serum (rho=0.92 for cohort 1, 0.93 for cohort 3) than in plasma (rho=0.88, cohort 1). Within-individual p-tau181 (Quanterix) and p-tau231 concentrations were twice higher in plasma versus serum, but p-tau181 (in-house, Gothenburg) levels were not statistically different. Bland-Altman plots revealed that the relative difference between serum/plasma was larger in the lower range. P-tau levels in paired plasma and serum correlated strongly with each other (rho=0.75–0.93) as well as with CSF Aβ 42 (rho= −0.56 to −0.59), p-tau and total-tau (rho=0.53–0.73). Based on the results, it seems possible that serum p-tau reflects the same pool of brain-secreted p-tau as in CSF; we estimated that less than 2% of CSF p-tau is found in serum, being same for both controls and AD. Conclusions Comparable diagnostic performances and strong correlations between serum versus plasma pairs suggest that p-tau analyses can be expanded to research cohorts and hospital systems that prefer serum to other blood matrices. However, absolute biomarker concentrations may not be interchangeable, indicating that plasma and serum samples should be used independently. These results should be validated in independent cohorts.
Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.
Le contrôle bibliographique ouvert
DOI retrouvé dans Crossref DOI retrouvé ; titre concordant.
- Titre Crossref
- Diagnostic value of serum versus plasma phospho-tau for Alzheimer’s disease
- Date Crossref
- 11/05/2022
- Éditeur
- Springer Science and Business Media LLC
- Type
- journal-article
Ce recoupement confirme des métadonnées liées au DOI. Il ne confirme ni la méthode ni les conclusions de l’étude, et il ne compte pas comme une seconde source scientifique indépendante.
Où se fait cette recherche
-
University of Gothenburg Department of Psychiatry and Neurochemistry pays non établi dans la noticeUniversité ou école supérieure
-
Sahlgrenska University Hospital Clinical Neurochemistry Laboratory pays non établi dans la noticeÉtablissement de santé
-
Ablynx (Belgium) pays non établi dans la noticeEntreprise
-
ADx NeuroSciences pays non établi dans la noticeEntreprise
-
UK Dementia Research Institute pays non établi dans la noticeStructure de recherche
-
UCL Queen Square Institute of Neurology pays non établi dans la noticeUniversité ou école supérieure
-
University College London pays non établi dans la noticeUniversité ou école supérieure
-
King's College London pays non établi dans la noticeUniversité ou école supérieure
-
Centre for Mental Health pays non établi dans la noticeÉtablissement de santé
-
Wallenberg Centre for Molecular and Translational Medicine pays non établi dans la noticeStructure de recherche
-
University of Pittsburgh Department of Psychiatry pays non établi dans la noticeUniversité ou école supérieure
-
UCL Institute of Neurology Department of Neurodegenerative Disease pays non établi dans la noticeStructure de recherche
Department of Psychiatry and Neurochemistry — University of Gothenburg, Clinical Neurochemistry Laboratory — Sahlgrenska University Hospital et Ablynx (Belgium), avec 9 autres affiliations.
Une affiliation ne permet pas de déduire la nationalité d’un auteur.